2023年1月20日 · 3D cultures of CD19 + B-cells induce a significant increase in B-cells and antibody production

Validation of CD3 + CD19 + cells and functional changes among patients with human immunodeficiency virus (HIV), Mycobacterium tuberculosis (Mtb) and HIV‐Mtb coinfection groups compared to healthy controls (HCs). (A) Eight surface markers (CD3, CD4, CD8, CD11b, CD19, CD45, CD56 and CD161) were used to construct a Visne map.

Anti-CD19 antibody B43 was utilized in a bispecific T-cell engager (BiTE) blinatumomab that demonstrated potency for the treatment of relapsed acute lymphoblastic leukemia. To gain insight into the mechanism of action of the antibody, the crystal structure of B43 Fab was determined in complex with CD19 and in the unbound form.

UniProt is the world’s leading high-quality, comprehensive and freely accessible resource of protein sequence and functional information.

2021年1月15日 · Here, we report a 3.8-angstrom structure of the CD19-CD81 complex bound to a therapeutic antigen-binding fragment, determined by cryo–electron microscopy (cryo-EM). The structure includes both the extracellular domains and the transmembrane helices of the complex, revealing a contact interface between the ectodomains that drives complex formation.

2023年12月8日 · CD19 is considered one of the most qualified antigens in the treatment of B-cell neoplasms. VHHs (nanobodies) are known for their physicochemical advantages over conventional mAbs rendering them suitable therapeutics and diagnostic tools. Herein, we aimed to isolate CD19-specific VHHs from a novel immune library using phage display.

2020年7月23日 · Cryo-EM structure of the B cell co-receptor CD19 bound to the tetraspanin CD81 Susa, K.J., Rawson, S., Kruse, A.C., Blacklow, S.C. (2021) Science 371: 300-304. DOI: https://doi.org/10.1126/science.abd9836

CD19双抗. 博纳吐单抗 （Blincyto）是安进研发的一款靶向CD19和CD3的双抗药物，一端可与CD19结合，另一端可与T细胞表面的CD3结合，进而介导T细胞对肿瘤细胞的溶解。博纳吐单抗用于治疗复发/难治性急性B淋巴细胞白血病，且在缓解期依旧有微小残留病灶（MRD）的 ...

2024年12月10日 · The in vitro CRA data showed that CD19-targeted CAR-T cells induced a diverse and concentration-dependent cytokine response led by a T H 1-profile (IFNγ, IL-2) and pro-inflammatory cytokines (IL-6, TNFα, MCP-1, IL-8, MIP-1b). It was also shown that different cellular components in this 3D co-culture system contributed to the CAR-T cell ...

Recent evidence suggests that resistance to CD19 chimeric antigen receptor (CAR)-modified T cell therapy may be due to the presence of CD19 isoforms that lose binding to the single-chain variable fragment (scFv) in current use. As such, further investigation of CARs recognize different epitopes of CD19 antigen may be necessary.